Skip to content

Buyuan Yizhi Granules for Mild Cognitive Impairment (Syndrome of Marrow Insufficiency and Phlegm-Turbidity): A Randomized Controlled Clinical Trial

Buyuan Yizhi Granules for Mild Cognitive Impairment (Syndrome of Marrow Insufficiency and Phlegm-Turbidity): A Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000827
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amnestic mild cognitive impairment

Interventions

Electroacupuncture group:Buyuan Yizhi Granules (composed of ginseng, ginger-processed pinellia tuber, etc.
administered continuously for 8 weeks, once every other day, 4 days per week) plus finger exercises (10–15 minutes before and after each herbal treatment, 4 times per week, 32 sessions in total over 8
Waiting Treatment Group:During the observation period, only finger exercise training was performed 4 times per week (synchronized with the treatment group), 10–15 minutes each time. Upon completion of

Sponsors

Affiliated Hospital of Shaanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Meet the Western medical diagnostic criteria for mild cognitive impairment and the traditional Chinese medical diagnostic criteria for the marrow insufficiency and phlegm-turbidity pattern; 2.Aged 40 to 80 years old (inclusive), with no gender restriction; 3.Right-handed, free of visual and auditory impairments, and able to cooperate with scale assessments; 4. No participation in other clinical trials in the past 3 months, no long-term use of specific medications before enrollment, or completion of the washout period; 5. Voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Presence of organic diseases that could explain cognitive impairment; 2.Presence of alarm symptoms or long-term use of non-steroidal anti-inflammatory drugs; 3.Cognitive impairment caused by identifiable specific etiologies; 4.Complicated with severe aphasia or neurological deficits, unable to cooperate with cognitive assessments; 5.Diagnosis of other types of dementia; 6.History of alcoholism, drug abuse, or psychotropic substance abuse; 7.History of acupuncture allergy or severe coagulation dysfunction (for the waiting-list control group); 8.Hypersensitivity to any herbal ingredient in Buyuan Yizhi Granules (such as ginseng, salvia miltiorrhiza, pinellia, etc.) (for the treatment group)

Design outcomes

Primary

MeasureTime frame
Alzheimer's Disease Assessment Scale - Cognitive Subscale;

Secondary

MeasureTime frame
Montreal Cognitive Assessment Scale;Mini-Mental State Examination (MMSE) Scale Score;Activities of Daily Living Scale Scoring;Pittsburgh Sleep Quality Index Scale;

Countries

China

Contacts

Public ContactDiwu Yongchang

Shaanxi University of Chinese Medicine

diwuyongchang@126.com13629189161

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026